{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:43:10Z","timestamp":1790772190178,"version":"4.1.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1111\/jth.15793","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T05:42:47Z","timestamp":1655703767000},"page":"1957-1970","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Structural insights into blood coagulation factor VIII: Procoagulant complexes, membrane binding, and antibody inhibition"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0472-7859","authenticated-orcid":false,"given":"Kenneth C.","family":"Childers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5997-9685","authenticated-orcid":false,"given":"Shaun C.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7982-5424","authenticated-orcid":false,"suffix":"Jr","given":"Paul Clint","family":"Spiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.15793_bb0010","first-page":"2428","article-title":"A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The recombinate study group","volume":"83","author":"Bray","year":"1994","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0015","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1055\/s-2002-32664","article-title":"Inhibitor development in previously untreated patients with hemophilia A: a prospective long\u2010term follow\u2010up comparing plasma\u2010derived and recombinant products","volume":"28","author":"Kreuz","year":"2002","journal-title":"Semin Thromb Hemost"},{"key":"10.1111\/jth.15793_bb0020","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1182\/blood-2008-03-143586","article-title":"Acquired factor VIII inhibitors","volume":"112","author":"Franchini","year":"2008","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0025","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood.2020010331","article-title":"A factor VIIIa\u2010mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice","volume":"138","author":"Ostergaard","year":"2021","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0030","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII\u2010mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"Shima","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15793_bb0035","doi-asserted-by":"crossref","first-page":"e12631","DOI":"10.1002\/rth2.12631","article-title":"Recombinant porcine factor VIII: lessons from the past and place in the management of hemophilia A with inhibitors in 2021","volume":"5","author":"Dargaud","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1111\/jth.15793_bb0040","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1182\/bloodadvances.2017013482","article-title":"FVIII proteins with a modified immunodominant T\u2010cell epitope exhibit reduced immunogenicity and normal FVIII activity","volume":"2","author":"Ettinger","year":"2018","journal-title":"Blood Adv"},{"key":"10.1111\/jth.15793_bb0045","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1111\/jth.15497","article-title":"Tolerogenic form of factor VIII to prevent inhibitor development in the treatment of hemophilia A","volume":"19","author":"Nguyen","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15793_bb0050","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1111\/jth.15413","article-title":"Development of a novel fully functional coagulation factor VIII with reduced immunogenicity utilizing an in silico prediction and deimmunization approach","volume":"19","author":"Winterling","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15793_bb0055","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","article-title":"Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A","volume":"123","author":"Mahlangu","year":"2014","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0060","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1182\/blood.2019001292","article-title":"BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice","volume":"135","author":"Seth Chhabra","year":"2020","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0065","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nbt.3677","article-title":"Enhancing the pharmaceutical properties of protein drugs by ancestral sequence reconstruction","volume":"35","author":"Zakas","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1111\/jth.15793_bb0070","doi-asserted-by":"crossref","first-page":"10363","DOI":"10.1021\/bi00107a001","article-title":"The coagulation cascade: initiation, maintenance, and regulation","volume":"30","author":"Davie","year":"1991","journal-title":"Biochemistry"},{"key":"10.1111\/jth.15793_bb0075","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1016\/S0021-9258(18)47430-3","article-title":"A major factor VIII binding domain resides within the amino\u2010terminal 272 amino acid residues of von Willebrand factor","volume":"262","author":"Foster","year":"1987","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.15793_bb0080","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1016\/S0021-9258(19)69627-4","article-title":"The role of phospholipid and factor VIIIa in the activation of bovine factor X","volume":"256","author":"van Dieijen","year":"1981","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.15793_bb0085","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood.V80.9.2159.2159","article-title":"Molecular basis of inherited human antithrombin deficiency","volume":"80","author":"Blajchman","year":"1992","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0090","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/S0021-9258(19)40071-9","article-title":"pH\u2010dependent denaturation of thrombin\u2010activated porcine factor VIII","volume":"265","author":"Lollar","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.15793_bb0095","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1074\/jbc.271.8.3982","article-title":"Activated protein C\u2010catalyzed proteolysis of factor VIIIa alters its interactions within factor Xase","volume":"271","author":"Regan","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.15793_bb0100","doi-asserted-by":"crossref","first-page":"6508","DOI":"10.1073\/pnas.86.17.6508","article-title":"Differential proteolytic activation of factor VIII\u2010von Willebrand factor complex by thrombin","volume":"86","author":"Hill\u2010Eubanks","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/jth.15793_bb0105","doi-asserted-by":"crossref","first-page":"10451","DOI":"10.1016\/S0021-9258(19)81537-5","article-title":"Association of the factor VIII light chain with von Willebrand factor","volume":"263","author":"Lollar","year":"1988","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.15793_bb0110","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1073\/pnas.85.8.2429","article-title":"Proteolytic requirements for thrombin activation of anti\u2010hemophilic factor (factor VIII)","volume":"85","author":"Pittman","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/jth.15793_bb0115","doi-asserted-by":"crossref","first-page":"8546","DOI":"10.1074\/jbc.270.15.8546","article-title":"Cleavage of factor VIII light chain is required for maximal generation of factor VIIIa activity","volume":"270","author":"Regan","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.15793_bb0120","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.str.2008.03.001","article-title":"Crystal structure of human factor VIII: implications for the formation of the factor IXa\u2010factor VIIIa complex","volume":"16","author":"Ngo","year":"2008","journal-title":"Structure"},{"key":"10.1111\/jth.15793_bb0125","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1182\/blood-2007-08-109918","article-title":"The tertiary structure and domain organization of coagulation factor VIII","volume":"111","author":"Shen","year":"2008","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0130","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1515\/hsz-2012-0298","article-title":"Evaluation of the metal binding sites in a recombinant coagulation factor VIII identifies two sites with unique metal binding properties","volume":"394","author":"Svensson","year":"2013","journal-title":"Biol Chem"},{"key":"10.1111\/jth.15793_bb0135","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/jth.13700","article-title":"The structural basis for the functional comparability of factor VIII and the long\u2010acting variant recombinant factor VIII Fc fusion protein","volume":"15","author":"Leksa","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15793_bb0140","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/jth.14621","article-title":"The 3.2 A structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain","volume":"18","author":"Smith","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15793_bb0145","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/mt.2009.35","article-title":"Directed engineering of a high\u2010expression chimeric transgene as a strategy for gene therapy of hemophilia A","volume":"17","author":"Doering","year":"2009","journal-title":"Mol Ther"},{"key":"10.1111\/jth.15793_bb0150","doi-asserted-by":"crossref","first-page":"6546","DOI":"10.1074\/jbc.M312451200","article-title":"Identification of porcine coagulation factor VIII domains responsible for high level expression via enhanced secretion","volume":"279","author":"Doering","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.15793_bb0155","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/mt.2010.239","article-title":"Lentiviral vector platform for production of bioengineered recombinant coagulation factor VIII","volume":"19","author":"Spencer","year":"2011","journal-title":"Mol Ther"},{"key":"10.1111\/jth.15793_bb0160","first-page":"536","article-title":"Metal identification in human anti\u2010hemophilia A factor (factor VIII)","volume":"316","author":"Bihoreau","year":"1993","journal-title":"C R Acad Sci III"},{"key":"10.1111\/jth.15793_bb0165","doi-asserted-by":"crossref","first-page":"27428","DOI":"10.1074\/jbc.272.43.27428","article-title":"Identification and functional requirement of Cu(I) and its ligands within coagulation factor VIII","volume":"272","author":"Tagliavacca","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.15793_bb0170","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood.V97.3.685","article-title":"Hemophilia A mutations associated with 1\u2010stage\/2\u2010stage activity discrepancy disrupt protein\u2010protein interactions within the triplicated A domains of thrombin\u2010activated factor VIIIa","volume":"97","author":"Pipe","year":"2001","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0175","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1182\/blood-2015-04-641688","article-title":"Mapping the interaction between factor VIII and von Willebrand factor by electron microscopy and mass spectrometry","volume":"126","author":"Chiu","year":"2015","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0180","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2013-07-517086","article-title":"Solution structure of the major factor VIII binding region on von Willebrand factor","volume":"123","author":"Shiltagh","year":"2014","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0185","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/bjh.17580","article-title":"Haemophilia: factoring in new therapies","volume":"194","author":"Fassel","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.15793_bb0190","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/hae.14123","article-title":"Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy","volume":"26","author":"Meeks","year":"2020","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15793_bb0195","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1046\/j.1538-7836.2003.00348.x","article-title":"An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa","volume":"1","author":"Gale","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15793_bb0200","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1160\/TH14-01-0086","article-title":"Enhanced factor VIIIa stability of A2 domain interface variants results from an increased apparent affinity for the A2 subunit. Results from an increased apparent affinity for the A2 subunit","volume":"112","author":"Monaghan","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.15793_bb0205","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/jth.13292","article-title":"Stabilizing interactions between D666\u2010S1787 and T657\u2010Y1792 at the A2\u2010A3 interface support factor VIIIa stability in the blood clotting pathway","volume":"14","author":"Monaghan","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15793_bb0210","doi-asserted-by":"crossref","first-page":"14020","DOI":"10.1074\/jbc.M114.550566","article-title":"Cofactor activity in factor VIIIa of the blood clotting pathway is stabilized by an interdomain bond between His281 and Ser524 formed in factor VIII","volume":"289","author":"Wakabayashi","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.15793_bb0215","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","article-title":"Pegylated, full\u2010length, recombinant factor VIII for prophylactic and on\u2010demand treatment of severe hemophilia A","volume":"126","author":"Konkle","year":"2015","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0220","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1172\/JCI108788","article-title":"Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease","volume":"60","author":"Weiss","year":"1977","journal-title":"J Clin Invest"},{"key":"10.1111\/jth.15793_bb0225","first-page":"34","article-title":"Molecular genetics of von Willebrand disease","volume":"41","author":"Mazurier","year":"1998","journal-title":"Ann Genet"},{"key":"10.1111\/jth.15793_bb0230","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1182\/blood-2018-01-829523","article-title":"A factor VIII\u2010nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation","volume":"132","author":"Muczynski","year":"2018","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0235","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1111\/jth.15480","article-title":"Increased potency of recombinant VWF D'D3 albumin fusion proteins engineered for enhanced affinity for coagulation factor VIII","volume":"19","author":"Chia","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15793_bb0240","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/blood-2013-11-540534","article-title":"A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice","volume":"124","author":"Yee","year":"2014","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0245","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1182\/blood.2020009197","article-title":"Molecular determinants of the factor VIII\/von Willebrand factor complex revealed by BIVV001 cryo\u2010electron microscopy","volume":"137","author":"Fuller","year":"2021","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0250","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.bpj.2019.07.007","article-title":"Interaction between the a3 region of factor VIII and the TIL'E' somains of the von Willebrand factor","volume":"117","author":"Dagil","year":"2019","journal-title":"Biophys J"},{"key":"10.1111\/jth.15793_bb0255","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/jth.14668","article-title":"Unique surface\u2010exposed hydrophobic residues in the C1 domain of factor VIII contribute to cofactor function and von Willebrand factor binding","volume":"18","author":"Przeradzka","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15793_bb0260","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1182\/blood-2015-04-641696","article-title":"Visualization of an N\u2010terminal fragment of von Willebrand factor in complex with factor VIII","volume":"126","author":"Yee","year":"2015","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0265","doi-asserted-by":"crossref","first-page":"11601","DOI":"10.1016\/S0021-9258(19)78167-8","article-title":"A role for the C2 domain of factor VIII in binding to von Willebrand factor","volume":"269","author":"Saenko","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.15793_bb0270","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1182\/blood-2018-10-876300","article-title":"The von Willebrand factor D'D3 assembly and structural principles for factor VIII binding and concatemer biogenesis","volume":"133","author":"Dong","year":"2019","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0275","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1021\/bi00350a035","article-title":"Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity","volume":"25","author":"Eaton","year":"1986","journal-title":"Biochemistry"},{"key":"10.1111\/jth.15793_bb0280","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0049-3848(87)90223-4","article-title":"Factor VIII coagulant moiety binds to platelets by binding to phospholipids of the platelet membrane","volume":"45","author":"Muntean","year":"1987","journal-title":"Thromb Res"},{"key":"10.1111\/jth.15793_bb0285","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1111\/jth.14961","article-title":"Discordance between platelet\u2010supported and vesicle\u2010supported factor VIII activity in the presence of anti\u2010C2 domain inhibitory antibodies","volume":"18","author":"Chatterjee","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15793_bb0290","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood-2015-01-620245","article-title":"Platelet binding sites for factor VIII in relation to fibrin and phosphatidylserine","volume":"126","author":"Gilbert","year":"2015","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0295","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1182\/blood.V86.5.1811.bloodjournal8651811","article-title":"Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid\u2010binding site","volume":"86","author":"Scandella","year":"1995","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0300","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/46601","article-title":"Structure of the C2 domain of human factor VIII at 1.5 A resolution","volume":"402","author":"Pratt","year":"1999","journal-title":"Nature"},{"key":"10.1111\/jth.15793_bb0305","doi-asserted-by":"crossref","first-page":"8824","DOI":"10.1074\/jbc.M109.080168","article-title":"Trp2313\u2010His2315 of factor VIII C2 domain is involved in membrane binding: structure of a complex between the C2 domain and an inhibitor of membrane binding","volume":"285","author":"Liu","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.15793_bb0310","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/46594","article-title":"Crystal structures of the membrane\u2010binding C2 domain of human coagulation factor V","volume":"402","author":"Macedo\u2010Ribeiro","year":"1999","journal-title":"Nature"},{"key":"10.1111\/jth.15793_bb0315","doi-asserted-by":"crossref","first-page":"9577","DOI":"10.1021\/bi00088a009","article-title":"Specific membrane binding of factor VIII is mediated by O\u2010phospho\u2010L\u2010serine, a moiety of phosphatidylserine","volume":"32","author":"Gilbert","year":"1993","journal-title":"Biochemistry"},{"key":"10.1111\/jth.15793_bb0320","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1182\/blood.2020008940","article-title":"Structure of blood coagulation factor VIII in complex with an anti\u2010C1 domain pathogenic antibody inhibitor","volume":"137","author":"Gish","year":"2021","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0325","doi-asserted-by":"crossref","first-page":"697602","DOI":"10.3389\/fimmu.2021.697602","article-title":"Structure of blood coagulation factor VIII in complex with an anti\u2010C2 domain non\u2010classical, pathogenic antibody inhibitor","volume":"12","author":"Ronayne","year":"2021","journal-title":"Front Immunol"},{"key":"10.1111\/jth.15793_bb0330","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood.V98.1.13","article-title":"Structure of a factor VIII C2 domain\u2010immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII","volume":"98","author":"Spiegel","year":"2001","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0335","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2013-08-519124","article-title":"Structure of the factor VIII C2 domain in a ternary complex with 2 inhibitor antibodies reveals classical and nonclassical epitopes","volume":"122","author":"Walter","year":"2013","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0340","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/978-3-030-58971-4_2","article-title":"Factor VIII and factor V membrane bound complexes","volume":"96","author":"Stoilova\u2010McPhie","year":"2021","journal-title":"Subcell Biochem"},{"key":"10.1111\/jth.15793_bb0345","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/blood-2007-01-068957","article-title":"The factor VIII C1 domain contributes to platelet binding","volume":"111","author":"Hsu","year":"2008","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0350","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1182\/blood-2010-08-301663","article-title":"A membrane\u2010interactive surface on the factor VIII C1 domain cooperates with the C2 domain for cofactor function","volume":"117","author":"Lu","year":"2011","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0355","doi-asserted-by":"crossref","first-page":"6374","DOI":"10.1074\/jbc.M104732200","article-title":"Four hydrophobic amino acids of the factor VIII C2 domain are constituents of both the membrane\u2010binding and von Willebrand factor\u2010binding motifs","volume":"277","author":"Gilbert","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.15793_bb0360","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1182\/blood-2009-01-197707","article-title":"Factor VIII C1 domain residues Lys 2092 and Phe 2093 contribute to membrane binding and cofactor activity","volume":"114","author":"Meems","year":"2009","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0365","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2016-02-701805","article-title":"High\u2010affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors","volume":"128","author":"Batsuli","year":"2016","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0370","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1182\/blood-2007-06-096842","article-title":"Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation","volume":"110","author":"Meeks","year":"2007","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0375","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1042\/BJ20140121","article-title":"Changes in the factor VIII C2 domain upon membrane binding determined by hydrogen\u2010deuterium exchange MS","volume":"461","author":"Pantazatos","year":"2014","journal-title":"Biochem J"},{"key":"10.1111\/jth.15793_bb0380","doi-asserted-by":"crossref","first-page":"7398","DOI":"10.1021\/bi992735q","article-title":"Insertion loop 256\u2010268 in coagulation factor IX restricts enzymatic activity in the absence but not in the presence of factor VIII","volume":"39","author":"Kolkman","year":"2000","journal-title":"Biochemistry"},{"key":"10.1111\/jth.15793_bb0385","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1074\/jbc.M210722200","article-title":"Physiological fIXa activation involves a cooperative conformational rearrangement of the 99\u2010loop","volume":"278","author":"Sichler","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.15793_bb0390","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/j.str.2009.10.011","article-title":"Structural basis of the cofactor\u2010 and substrate\u2010assisted activation of human coagulation factor IXa","volume":"17","author":"Zogg","year":"2009","journal-title":"Structure"},{"key":"10.1111\/jth.15793_bb0395","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1182\/blood.2020005593","article-title":"Factor VIII\u2010driven changes in activated factor IX explored by hydrogen\u2010deuterium exchange mass spectrometry","volume":"136","author":"Freato","year":"2020","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0400","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X\u2010linked thrombophilia with a mutant factor IX (factor IX Padua)","volume":"361","author":"Simioni","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15793_bb0405","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3324\/haematol.2019.216713","article-title":"Factor IX alteration p.Arg338Gln (FIX Shanghai) potentiates FIX clotting activity and causes thrombosis","volume":"106","author":"Wu","year":"2021","journal-title":"Haematologica"},{"key":"10.1111\/jth.15793_bb0410","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1182\/bloodadvances.2019000405","article-title":"Evolutionary insights into coagulation factor IX Padua and other high\u2010specific\u2010activity variants","volume":"5","author":"Samelson\u2010Jones","year":"2021","journal-title":"Blood Adv"},{"key":"10.1111\/jth.15793_bb0415","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1182\/blood.2021010684","article-title":"Cryo\u2010EM structures of human coagulation factors V and Va","volume":"137","author":"Ruben","year":"2021","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0420","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1182\/blood-2013-06-511733","article-title":"Crystal structure of the prothrombinase complex from the venom of Pseudonaja textilis","volume":"122","author":"Lechtenberg","year":"2013","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0425","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1182\/blood.2022015807","article-title":"Cryo\u2010EM structure of the prothrombin\u2010prothrombinase complex","volume":"139","author":"Ruben","year":"2022","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0430","doi-asserted-by":"crossref","first-page":"17012","DOI":"10.1016\/S0021-9258(18)41886-8","article-title":"The active site of factor IXa is located far above the membrane surface and its conformation is altered upon association with factor VIIIa. A fluorescence study","volume":"267","author":"Mutucumarana","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.15793_bb0435","doi-asserted-by":"crossref","first-page":"16302","DOI":"10.1074\/jbc.M011680200","article-title":"Factor IXa:factor VIIIa interaction. helix 330\u2010338 of factor IXa interacts with residues 558\u2010565 and spatially adjacent regions of the a2 subunit of factor VIIIa","volume":"276","author":"Bajaj","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.15793_bb0440","doi-asserted-by":"crossref","first-page":"20522","DOI":"10.1016\/S0021-9258(17)32024-0","article-title":"Factor VIIIa A2 subunit residues 558\u2010565 represent a factor IXa interactive site","volume":"269","author":"Fay","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.15793_bb0445","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1074\/jbc.M804955200","article-title":"The factor VIIIa C2 domain (residues 2228\u20102240) interacts with the factor IXa Gla domain in the factor Xase complex","volume":"284","author":"Soeda","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.15793_bb0450","doi-asserted-by":"crossref","first-page":"18477","DOI":"10.1074\/jbc.274.26.18477","article-title":"Protease and EGF1 domains of factor IXa play distinct roles in binding to factor VIIIa. Importance of helix 330 (helix 162 in chymotrypsin) of protease domain of factor IXa in its interaction with factor VIIIa","volume":"274","author":"Mathur","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.15793_bb0455","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1074\/jbc.M107753200","article-title":"The factor IXa second epidermal growth factor (EGF2) domain mediates platelet binding and assembly of the factor X activating complex","volume":"277","author":"Wilkinson","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.15793_bb0460","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.3389\/fimmu.2019.02991","article-title":"Tolerating factor VIII: recent progress","volume":"10","author":"Lacroix\u2010Desmazes","year":"2019","journal-title":"Front Immunol"},{"key":"10.1111\/jth.15793_bb0465","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.V92.2.496","article-title":"Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor","volume":"92","author":"Jacquemin","year":"1998","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0470","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1055\/s-0038-1651588","article-title":"A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine","volume":"69","author":"Shima","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.15793_bb0475","doi-asserted-by":"crossref","first-page":"27424","DOI":"10.1074\/jbc.271.44.27424","article-title":"Slowed release of thrombin\u2010cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition","volume":"271","author":"Saenko","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.15793_bb0480","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1182\/blood-2016-11-751347","article-title":"Frequency and epitope specificity of anti\u2010factor VIII C1 domain antibodies in acquired and congenital hemophilia A","volume":"130","author":"Kahle","year":"2017","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0485","doi-asserted-by":"crossref","first-page":"9905","DOI":"10.1074\/jbc.M112.424564","article-title":"Characterization and solution structure of the factor VIII C2 domain in a ternary complex with classical and non\u2010classical inhibitor antibodies","volume":"288","author":"Walter","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.15793_bb0490","doi-asserted-by":"crossref","first-page":"17216","DOI":"10.1038\/srep17216","article-title":"Structure of the human factor VIII C2 domain in complex with the 3E6 inhibitory antibody","volume":"5","author":"Wuerth","year":"2015","journal-title":"Sci Rep"},{"key":"10.1111\/jth.15793_bb0495","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/j.1538-7836.2010.03878.x","article-title":"A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF\u2010binding site distant from its epitope","volume":"8","author":"Dimitrov","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15793_bb0500","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1182\/blood-2012-09-456582","article-title":"The diversity of the immune response to the A2 domain of human factor VIII","volume":"121","author":"Markovitz","year":"2013","journal-title":"Blood"},{"key":"10.1111\/jth.15793_bb0505","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1182\/blood-2015-09-670034","article-title":"A subset of high\u2010titer anti\u2010factor VIII A2 domain antibodies is responsive to treatment with factor VIII","volume":"127","author":"Eubanks","year":"2016","journal-title":"Blood"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15793","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.15793","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622021067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622021067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15793","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:35:44Z","timestamp":1761536144000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622021067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":100,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1538783622021067"],"URL":"https:\/\/doi.org\/10.1111\/jth.15793","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural insights into blood coagulation factor VIII: Procoagulant complexes, membrane binding, and antibody inhibition","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.15793","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}